Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pfizer
(NY:
PFE
)
28.71
-0.17 (-0.59%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pfizer
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
33
34
Next >
Promising Research in Fight Against Breast Cancer Being Amplified by an Active Biotech Sector
January 20, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 20, 2021 – USA News Group – As the 2021 San Antonio Breast Cancer Symposium (SABCS) comes to a close, many of this year’s...
Via
FinancialNewsMedia
Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies
January 18, 2022
New York, NY, and Tel Aviv, ISRAEL - (NewMediaWire) - January 18, 2022 - Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today released videos of...
Via
NewMediaWire
Exposures
COVID-19
U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis
January 14, 2022
From
Pfizer Inc.
Via
Business Wire
Watch for Continued Gains in Shares of Pfizer Inc. (PFE)
December 20, 2021
Via
Investor Brand Network
Exposures
COVID-19
Pfizer Inc. (PFE) Climbs to Annual-High Share Price
December 15, 2021
Via
Investor Brand Network
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019
January 14, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC – January 14, 2022 – USA News Group – Cancer cases are on the rise, according to a new study comparing the number of cancer...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
DGE’s Investigator Initiated Trials Summit
January 14, 2022
Via
Investor Brand Network
Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released
January 12, 2022
From
Pfizer Inc.
Via
Business Wire
With Full Enrollment Complete In Its Phase 2 COVID-Related GI Treatment Trial, First Wave Bio Could Earn An EUA Sooner Than Later (NASDAQ: FWBI)
January 11, 2022
Via
AB Newswire
Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
January 10, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
January 10, 2022
From
Pfizer Inc.
Via
Business Wire
New Study Explores Whether mRNA Vaccines Could Help Against Cancer
January 05, 2022
Via
Investor Brand Network
Exposures
COVID-19
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
January 05, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19
January 04, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
January 04, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older
January 03, 2022
From
Pfizer Inc.
Via
Business Wire
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
December 30, 2021
From
Pfizer Inc.
Via
Business Wire
Pfizer Invites Public to View and Listen to Webcast of February 8 Conference Call with Analysts
December 28, 2021
From
Pfizer Inc.
Via
Business Wire
Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer's Paxlovid Approval, Tollovir(TM) Phase 2 & COVID Testing
December 23, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
COVID-19
Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment
December 22, 2021
From
Pfizer Inc.
Via
Business Wire
Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
December 22, 2021
From
Pfizer Inc.
Via
Business Wire
Pfizer’s VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate
December 20, 2021
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply
December 20, 2021
From
Pfizer Inc.
Via
Business Wire
EMA Issues Advice for Potential Early Use of Pfizer’s Novel COVID-19 Oral Antiviral Candidate
December 16, 2021
From
Pfizer Inc.
Via
Business Wire
U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis
December 14, 2021
From
Pfizer Inc.
Via
Business Wire
Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death
December 14, 2021
From
Pfizer Inc.
Via
Business Wire
Pfizer to Acquire Arena Pharmaceuticals
December 13, 2021
From
Pfizer Inc.
Via
Business Wire
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
December 12, 2021
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Pfizer Declares First-Quarter 2022 Dividend
December 10, 2021
From
Pfizer Inc.
Via
Business Wire
European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis
December 10, 2021
From
Pfizer Inc.
Via
Business Wire
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.